Biochemical and clinical pharmacology of 5-fluorouracil

ONCOLOGY

Volumn 12, Issue 10 SUPPL. 7, 1998, Pages 13-18

  Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' DEOXYFLUOROURIDINE; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; PROTEIN P53; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

APOPTOSIS; BIOCHEMISTRY; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PATIENT SELECTION; STOMACH CANCER;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; DIHYDROURACIL DEHYDROGENASE (NADP); DNA, NEOPLASM; FLUOROURACIL; HUMANS; NEOPLASMS; OXIDOREDUCTASES; PHENOTYPE;

EID: 0031730159     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Sotos GA, Allegra CJ: Biochemical modulation of cancer chemotherapy, in Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antineoplastic Drug Development and Pharmacology, pp 143-187. New York, Marcel Dekker, Inc., 1996.
2. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997.
3. Peters GJ, Jansen G: Resistance to antimetabolites, in Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antineoplastic Drug Development and Pharmacology, pp 543-585, New York, Marcel Dekker, Inc., 1996.
4. Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019, 1998.
5. Lenz H-J, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182, 1996.
6. Leichman LG, Lenz H-J, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229, 1997.
7. Lenz H-J, Hayashi K, Salonga D, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243-1250, 1998.
8. Cheradame S, Etienne MC, Formento P, et al: Tumoral reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients. J Clin Oncol 15:2604-2610, 1997.
9. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995.
10. Danenberg K, Salonga D, Park JM, et al: Dihydropyrimidine dehydrogenase and thymidy-late synthase gene expressions identify a high percentage of colorectal tumors responding to 5- fluorouracil. Proc Am Soc Clin Oncol 17:258a, 1998.
11. Grem JL: 5-Fluoropyrimidines, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy, pp 149-211. Philadelphia, Lippincott-Raven, 1996.
12. Harris BE, Song R, Soong S-J, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990.
13. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253, 1994.
14. Lu Z, Zhang R, Carpenter JT, et al: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4:325-329, 1998.
15. Fleming RA, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992.
16. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993.
17. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome. Cancer 68:499-501, 1991.
18. Santini J, Milano G, Thyss A, et al: FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290, 1989.
19. Milano G, Etienne MC, Renee N, et al: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291-1295, 1994.
20. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al: Relationship between 5-fluorouracil dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77:441-451, 1996.
21. Gamelin E, Boisdron-Celle M, Delva R, et al: Long term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16:1470-1478, 1998.
22. Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690, 1998.
23. Porter DJT, Chestnut WG, Merrill BM, et al: Mechanism based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267:5236-5242, 1992.
24. Schilsky RL, Hohneker J, Ratain MJ, et al: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16:1450-1457, 1998.
25. Baker SD, Diasio R, Lucas VS, et al: Phase I and pharmacologic study of oral 5-fluorouracil on a chronic 28 day schedule in combination with the dihydropyrimidine dehydrogenase inactivator 776C85. Proc Am Soc Clin Oncol 15:486, 1996.
26. Baker SD, Khor SP, Adjei AA, et al: Pharmacokinetic, oral bioavailability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096, 1996.
27. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994.
28. Schilsky R, Bukowski R, Burris H et al: A phase II study of a five day regimen of oral 5 fluorouracil plus 776C85 with or without leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 16:271a, 1997.
29. Mani S, Beck T, Chevlen E, et al: A phase II open label study to evaluate a 28 day regimen of oral 5-fluorouracil plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 17:281a, 1998.